OBJECTIVE: To observe and compare the immunoreaction levels of revaccination with different hepatitis B vaccine in healthy population of different age groups. METHODS: Multi-stage random sampling method was used, 2 to 4 years old, 6 to 8 years old, 13 to 15 years old and 16 to 40 years old healthy people had been sampled in five towns according to different district. Screened those people's HBV serologic markers by ELISA, the person whose HBV serologic markers were all negative and had been vaccinated three doses of hepatitis B vaccine would be the revaccination recipients. Six kinds of recombinant Hepatitis B vaccine (yeast-derived or CHO cells) with 5 microg, 10 microg and 20 microg were used for the recipients on a 0-1-6 month schedule. RESULTS: Successful rates of revaccination and the median of antibody levels (mIU/ml) in the recipients were 94.34% and 226.53 in 5 microg yeast-derived vaccine group, 86.46% and 175.36 in 10 microg yeast-derived vaccine group, 97.39% and 331.44 in 10 microg CHO cells vaccine group, 91.30% and 439.01 in 10 microg Hansenula yeast-derived vaccine group, 99.20% and 386.66 in 20 microg CHO cells vaccine group, 89.04% and 372.97 in 20 microg yeast-derived vaccine group, 98.25% and 353.42 in 2 to 4 years old group, 96.80% and 320.31 in 6 to 8 years old group, 94.67% and 262.12 in 13 to 15 years old group, 87.76% and 305.24 in 16 to 40 years old group. CONCLUSION: Age, vaccine and dose were the most important factors to affect the immunoreaction levels of revaccination. There was an age-specific decline in immunogenicity, the immunoreaction levels of revaccination will be improved by changing vaccine.
OBJECTIVE: To observe and compare the immunoreaction levels of revaccination with different hepatitis B vaccine in healthy population of different age groups. METHODS: Multi-stage random sampling method was used, 2 to 4 years old, 6 to 8 years old, 13 to 15 years old and 16 to 40 years old healthy people had been sampled in five towns according to different district. Screened those people's HBV serologic markers by ELISA, the person whose HBV serologic markers were all negative and had been vaccinated three doses of hepatitis B vaccine would be the revaccination recipients. Six kinds of recombinant Hepatitis B vaccine (yeast-derived or CHO cells) with 5 microg, 10 microg and 20 microg were used for the recipients on a 0-1-6 month schedule. RESULTS: Successful rates of revaccination and the median of antibody levels (mIU/ml) in the recipients were 94.34% and 226.53 in 5 microg yeast-derived vaccine group, 86.46% and 175.36 in 10 microg yeast-derived vaccine group, 97.39% and 331.44 in 10 microg CHO cells vaccine group, 91.30% and 439.01 in 10 microg Hansenula yeast-derived vaccine group, 99.20% and 386.66 in 20 microg CHO cells vaccine group, 89.04% and 372.97 in 20 microg yeast-derived vaccine group, 98.25% and 353.42 in 2 to 4 years old group, 96.80% and 320.31 in 6 to 8 years old group, 94.67% and 262.12 in 13 to 15 years old group, 87.76% and 305.24 in 16 to 40 years old group. CONCLUSION: Age, vaccine and dose were the most important factors to affect the immunoreaction levels of revaccination. There was an age-specific decline in immunogenicity, the immunoreaction levels of revaccination will be improved by changing vaccine.